A polyvalent melanoma vaccine induces a CD8 T-cell response to MART-1 and MAGE-3 peptides (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


A polyvalent melanoma vaccine induces a CD8 T-cell response to MART-1 and MAGE-3 peptides (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 37:A3350 1996. Unique Identifier : AIDSLINE ICDB/97633350
Reynolds SR; Vukmanovic S; Oratz R; Shapiro RL; Bystryn J-C; The Ronald O. Perelman Dept. of Dermatology, New York Univ.; Medical Center, New York, NY 10016

Abstract: Melanoma patients immunized with a polyvalent vaccine were assessed for their peripheral blood lymphocyte (PBL) responses to the melanoma peptides MART-1, MAGE-3 and a control peptide from falciparum malaria. The vaccine was prepared from shed melanoma antigens, bound to alum, and administered sc every 3 weeks x 4 to 10 HLA-A2+ patients. The peptides studied are all HLA-A2 restricted. Seven (70%) of the patients had a significant T-cell response to MART-1 and/or MAGE-3-pulsed A2+ melanoma targets compared to control peptide as measured by IFN-gamma release. Three patients responded to MART-1 and five to MAGE-3. The responses appeared to be vaccine-induced, since two patients studied in detail had no detectable peptide-specific cells before immunization. After treatment, both had a statistically significant increase in CD8 IFN-gamma-secreting cells (400/10(6) PBL to MART-1 in one patient and 580/10(6) PBL to MAGE-3 in the other patient). The responses were abrogated by antibodies to CD8 or HLA-class I but not by anti-CD4, indicating they were CD8 mediated. These results show that a polyvalent vaccine can induce a CD8 response to MART-1 and MAGE-3, and provide direct evidence that these proteins can induce a T-cell response in humans.
Keywords: CD8-Positive T-Lymphocytes/*IMMUNOLOGY *Cancer Vaccines HLA-A2 Antigen/IMMUNOLOGY Melanoma/*IMMUNOLOGY Neoplasm Proteins/*IMMUNOLOGY ABSTRACTKWDcd8-positivet-lymphocytes/KWDimmunologyKWDcancervaccineshla-a2antigen/immunologymelanoma/KWDimmunologyneoplasmproteins/KWDimmunologyabstract
970330
M9731539

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .